Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are basal insulin glargine analogs with identical amino acid sequence and similar pharmacological profiles. ELEMENT 5, a Phase 3, prospective, randomized, multinational, two-arm, active-...
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus(R) insulin glargine in patients with type 1 diabetes mellitus or type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18: 159-168. doi: 10.1111/dom.12584Ilag LL, Deeg MA, Costigan T, et al. Evaluation of ...
Insulin glargine (100 units/mL; Basaglar or Lantus): Treatment of type 1 diabetes mellitus in adults and children ≥6 years of age or type 2 diabetes mellitus in adults who require long-acting insulin for control of hyperglycemia.Insulin glargine (300 units/mL; Toujeo): Treatment of type ...
英文别名:19:PN:WO03105888 PAGE:20 claimed protein;3:PN:WO2014161835 SEQID:11 claimed sequence;Basaglar;Glargin;Glargine;HOE 901;Insulin[A20a-glycine,B30a-arginine,B30b-arginine](human);Insulin[A21-glycine,B31-arginine,B32-arginine](human);Insulin glargine;LY 2963016;Lantus;Lantus R;Toujeo ...
Basaglar and Lantus are both forms of insulin glargine, but they are not interchangeable. Learn the key differences between Lantus and Basaglar.
部份中文甘精胰岛素处方资料(仅供参考)商品名:LANTUS英文名:Insulin glargine中文名:甘精胰岛素注射劑生产商:赛诺菲-安万特藥理類別:insulin glargine药理类别:抗糖尿病药物孕妇用药分级C 级:在对照的动物研究试验中显示该药学物对胚胎有不良反应(致畸胎性或杀胚胎性或其他),但未进行人体怀孕妇女研究;或者尚无对照的人体怀...
Lantus预填充笔式 100单位/毫升 10支X3毫升中文参考药品译名:甘精胰岛素商品名:LANTUS 英文名:Insulin glargine中文名:甘精胰岛素注射劑生产商:赛诺菲-安万特 药理类别:抗糖尿病药物孕妇用药分级C 级: 在对照的动物研究试验中显示该药学物对胚胎有不良反应(致畸胎性或杀胚胎性或其他),但未进行人体怀孕妇女研究;或者尚...
regardless of prior insulin glargine treatment," saidDavid Kendall, MD, vice president, Medical Affairs, Lilly Diabetes. "These data provide important additional evidence for the similarity of ABASAGLAR to Lantus in people with type 1 and type 2 diabetes and provide physicians further information ...
Lantus, INN insulin glargine European (地特胰岛素应用,酒店欧洲人).pdf,19 April 2012 EMA/CHMP/158966/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Lantus insulin glargine Procedure No.: EMEA/H/C/000284/II/0075 Note Variat
Insulin glargine; Insulin glargine; Insulin glargine; Insulin glargine; Insulin glargine; A21-Gly-B31-Arg-B32-Arg-insulin; Insulin Glargine EP/USP; Insulin, glycyl(A21)-arginyl(B31,B32)-; Lantus; Solostar; Solostar [insulin delivery pen]; Unii-2zm8cx04rz; View all 1.3 CAS No. 160337-95...